QualityStocks would like to highlight
GrowBLOX Sciences, Inc. (
OTCQB: GBLX), a biopharmaceutical research and development company, focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies for various medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm, to bring relief to patients in communities across the country.
In the company’s news,
GrowBLOX Sciences (“GB Sciences”) is a nature-inspired company employing a novel approach toward cannabis-based medicine. The company is focused on offering a turnkey business solution: transforming cannabis into safe and consistent medicine.
GB Sciences’ focus is on the research of indoor agriculture technology for the medical cannabis industry. The company merges state-of-the-art technologies in plant biology, cultivation and post-production processes in order to optimize safe, consistent medical cannabis. In doing so, the company is also pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm in order to bring relief to patients in communities across the country.
As part of its efforts to lock in industry standards, GB Sciences is developing a comprehensive line of highly effective cannabis-based therapies ranging from custom medical compounds to consumer health and beauty products. GB Sciences’ cultivation methodology ensures a consistent ratio of the plant’s medicinal properties for each and every harvest. This is a critical factor when creating formulations for standardized therapeutic products.
GB Sciences’ drug development program also endeavors to unlock the path to drug discovery and to provide novel cannabinoid therapies to patients with critically unmet needs. The company is developing the GrowBLOX system, a proprietary technology that allows for controlled growing conditions for the manufacture of toxin-free, natural, and medicinal-grade cannabis and cannabis concentrates. Starting with certified, cannabis plant-derived ingredients from the GrowBLOX technology suite, GB Sciences tests proprietary ratios of active ingredients in an accelerated drug development program. It also focuses on the research, testing and development of FDA-approved medical treatments and nutraceuticals using extracts from the cannabis sativa plant.
GrowBLOX Sciences is gearing up to cultivate the medical cannabis industry in new ways. The company’s science and research efforts power discovery, its engineering and design activities bring ideas into the real world, and its big data methodology drives continuous improvement.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
